대한간학회지 (Clinical and Molecular Hepatology)

  • 제24권4호
  • /
  • Pages.367-369
  • /
  • 2018
  • /
  • 2287-2728(pISSN)
  • /
  • 2287-285X(eISSN)
대한간학회 (The Korean Association for the Study of the Liver)
권호 표지
DOI QR코드

DOI QR Code

Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level

  • Jeon, Mi Young (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Kim, Beom Kyung (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Kim, Seung Up (Department of Internal Medicine, Yonsei University College of Medicine)
  • 투고 : 2018.08.27
  • 심사 : 2018.09.03
  • 발행 : 2018.12.25
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. https://doi.org/10.1001/jama.295.1.65
  2. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-398. https://doi.org/10.1016/j.jhep.2017.03.021
  3. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560-1599. https://doi.org/10.1002/hep.29800
  4. Cristina SJL, Marta CM, Mercedes GS, Almudena PM, Alvaro HM, Luis VSJ, et al. Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases. Clin Mol Hepatol 2018;24:384-391. https://doi.org/10.3350/cmh.2018.0004
  5. Zhu L, Jiang J, Zhai X, Baecker A, Peng H, Qian J, et al. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: a population-based cohort study. Liver Int. 2018 Jul 19. doi: 10.1111/liv.13933.
  6. Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 2012;56:533-540. https://doi.org/10.1016/j.jhep.2011.09.013
  7. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67:862-873. https://doi.org/10.1016/j.jhep.2017.06.003
  8. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009;58:111-117. https://doi.org/10.1136/gut.2008.157735
  9. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292. https://doi.org/10.1053/jhep.2003.50229
  10. Petta S, Maida M, Macaluso FS, Di Marco V, Camma C, Cabibi D, et al. The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology 2015;62:1101-1110. https://doi.org/10.1002/hep.27844
  11. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960-974. https://doi.org/10.1053/j.gastro.2008.01.034
  12. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7:40. https://doi.org/10.1186/1471-230X-7-40
  13. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alphainterferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-270.
  14. Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, et al. High risk of hepatocellular carcinoma and death in patients with immunetolerant- phase chronic hepatitis B. Gut 2018;67:945-952. https://doi.org/10.1136/gutjnl-2017-314904
  15. Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011;53:885-894. https://doi.org/10.1002/hep.24121

피인용 문헌

  1. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B vol.27, pp.2, 2021, https://doi.org/10.3350/cmh.2020.0216